Could PAR be the next CSL?, page-57

Pretty sure PAR has patent protection in place,  commercial exclusivity agreements in place.   As discussed difficult to replicate the molecular structure and even if they can they would need to go through a lengthy approval process.


Also, if you google (paradigm-biopharmaceuticals-alleviate-opiate-crisis-ground-breaking-discovery) it will lead to an article about why iPPS could be a game changer for OA treatment

After undergoing peer-review, the research has now been published in the scientific journal, PLoS One, titled “Human osteocyte expression of Nerve Growth Factor: the effect of PPS and implications for pain associated with knee osteoarthritis”.
According to the authors of the study, PPS (also known as Zilosul) is a promising therapeutic agent for blocking knee pain in individuals with knee osteoarthritis (KOA), although its mode of action in this context remains “unknown”.

Yes there is risk and everyone should have their own risk assessment and understand their own risk profiles before investing.   Nothing in life is guaranteed.   DYOR etc. But having said that there is a great community here with a lot of research and insights already done for people to understand PAR and its potential.

For me, I have invested and am ready to let it roll for the next 10 -15 years and hopefully reap the rewards.